Methods and compositions for determining a graft tolerant phenotype in a subject
View Patent ↗Methods are provided for determining whether a subject has a graft tolerant phenotype. In practicing the subject methods, the expression of at least 5 genes in a sample from the subject, e.g., a blood sample, is assayed to obtain a gene expression result for the at least 5 genes. The obtained gene expression result for the at least 5 genes is then employed to determine whether the subject has a graft tolerant phenotype. Also provided are compositions, systems and kits that find use in practicing the subject methods. The methods and compositions find use in a variety of applications, including the determination of an immunosuppressive therapy regimen.
1. A method of evaluating the expression levels of at least 5 genes selected from the group consisting of FAM110C, VNN1, ATXN1, BMP2K, CCL3L3, MYL2, KIF15, IP013, TMEM117, PDPN, PRPF4OB, NRTN, TSPAN7, CENPN, DOPEY2, AGBL3, ELAVL1, NUPL1, KLF5, MYLIP, ATXN3, ZDHHC17, PGM3, ZMYM2, OR10J3, SSX3, GNG13, KIAA1751, RGMA, IL1F8, GPHA2, MKL2, TRPV1, KRTAP13-1, OR13C4, and KCNE1, comprising:
providing a sample from a subject who has received an allograft;
contacting said sample with a collection of gene specific primers designed to selectively amplify expression products of said at least 5 genes,
wherein the at least 5 genes includes FAM110C;
wherein the primers are labelled and the collection of gene specific primers comprises primers for selectively amplifying the at least 5 genes; and
assessing, using said collection of gene specific primers, the amount of said expression products in said sample.
2. The method according to claim 1 , wherein said allograft is a renal allograft.
3. The method according to claim 1 , wherein said sample is a blood sample.
4. The method according to claim 3 , wherein said blood sample is a peripheral blood lymphocyte sample.
5. The method according to claim 1 , wherein said expression products are nucleic acid transcripts.
6. The method according to claim 5 , wherein said evaluating step comprises performing a RT-PCR assay.
7. The method according to claim 1 , wherein the expression levels of FAM110C and at least 10 genes from the group are evaluated.
8. The method according to claim 1 , wherein the expression levels of FAM110C and all of the genes from the group are evaluated.
9. The method according to claim 1 , wherein said assessing is quantitative.